

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed			1	
Dosing Accident	1		1	
Moribund Sacrifice	10	11	16	19
Natural Death	4	8	26	31
Survivors				
Terminal Sacrifice	35	31	5	
Animals Examined Microscopically	50	50	49	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(49)	(50)
Perforation	1			
Epithelium, Necrosis	1 [2.0]			
Periesophageal Tissue, Inflammation, Chronic Active	1 [2.0]			
Gallbladder	(49)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	2 [1.0]			
Inflammation, Chronic Active	1 [3.0]			
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Cyst			1 [4.0]	
Intestine Large, Rectum	(50)	(50)	(49)	(50)
Intestine Small, Duodenum	(50)	(50)	(49)	(50)
Intussusception		1 [4.0]		
Intestine Small, Ileum	(50)	(50)	(49)	(50)
Intestine Small, Jejunum	(50)	(50)	(49)	(50)
Liver	(50)	(50)	(49)	(50)
Amyloid Deposition		3 [2.7]	2 [2.0]	
Atypia Cellular		1 [2.0]		
Basophilic Focus		4	2	2
Clear Cell Focus	12	6	1	
Congestion			1 [4.0]	1 [3.0]
Eosinophilic Focus	5	1	3	
Hematopoietic Cell Proliferation	2 [1.5]	9 [1.4]	9 [1.4]	3 [1.3]
Hemorrhage	1 [2.0]		1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Infarct	1 [4.0]	1 [4.0]		
Infiltration Cellular, Lymphoid	7 [1.3]	16 [1.1]	11 [1.1]	2 [1.0]
Inflammation, Chronic Active	35 [1.2]	32 [1.1]	17 [1.3]	14 [1.1]
Mineralization	1 [1.0]	1 [2.0]		
Mixed Cell Focus	4	6		2
Pigmentation	2 [1.5]	1 [2.0]		
Tension Lipidosis	2 [2.0]	5 [1.8]	12 [2.5]	15 [2.1]
Thrombosis	1 [4.0]			
Bile Duct, Hyperplasia	1 [2.0]			
Hepatocyte, Necrosis	5 [2.2]	4 [2.5]	2 [2.5]	
Hepatocyte, Vacuolization Cytoplasmic	31 [2.0]	31 [1.7]	23 [1.2]	11 [1.1]
Mesentery	(5)	(5)	(4)	(2)
Fat, Fibrosis	4 [2.8]	2 [2.5]		
Fat, Inflammation, Chronic Active	3 [2.0]	5 [2.8]	3 [3.0]	1 [4.0]
Fat, Mineralization	1 [2.0]	2 [1.5]		
Fat, Necrosis	4 [4.0]	3 [4.0]	1 [4.0]	
Oral Mucosa	(0)	(1)	(0)	(0)
Gingival, Inflammation, Chronic Active		1 [3.0]		
Pancreas	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	6 [1.2]	5 [1.0]	1 [1.0]	
Inflammation, Chronic Active		2 [2.0]	1 [4.0]	1 [2.0]
Duct, Cyst	1 [4.0]			
Salivary Glands	(50)	(50)	(49)	(50)
Degeneration	1 [3.0]			
Infiltration Cellular, Lymphoid	43 [1.3]	34 [1.3]	22 [1.1]	4 [1.0]
Mineralization			1 [1.0]	
Stomach, Forestomach	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid			1 [2.0]	
Inflammation, Chronic Active	6 [2.3]	7 [1.7]	6 [2.0]	3 [2.3]
Epithelium, Cyst	1 [2.0]			
Epithelium, Hyperplasia	8 [2.5]	21 [1.4]	33 [1.7]	44 [2.0]
Epithelium, Ulcer	5 [3.4]	3 [2.7]	3 [2.7]	2 [2.5]
Stomach, Glandular	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	3 [1.0]	20 [1.5]	19 [1.6]	15 [1.8]
Infiltration Cellular, Mast Cell		1 [2.0]		
Inflammation, Chronic Active		1 [2.0]	1 [2.0]	1 [2.0]
Mineralization		4 [1.0]	6 [1.2]	13 [1.4]
Epithelium, Hyperplasia	1 [3.0]			
Epithelium, Hyperplasia, Focal		10 [1.8]	20 [1.9]	34 [2.0]
Epithelium, Ulcer			1 [3.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Epithelium, Glands, Cyst	5 [1.4]	18 [1.4]	21 [1.3]	26 [1.3]
Glands, Cyst			1 [1.0]	1 [1.0]
Tongue	(0)	(1)	(0)	(0)
Cyst, Multiple		1 [2.0]		
Artery, Inflammation, Chronic Active		1 [3.0]		
Tooth	(8)	(3)	(0)	(0)
Dysplasia	3 [3.0]			
Malformation	4	3		
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(49)	(50)
Hyperplasia	1 [3.0]			
Aorta, Inflammation, Chronic Active		2 [2.5]		
Aorta, Mineralization			6 [1.2]	8 [1.4]
Heart	(50)	(50)	(49)	(50)
Cardiomyopathy	5 [1.4]	5 [2.2]	17 [1.7]	9 [1.4]
Hyperplasia, Atypical		2 [2.5]		
Infiltration Cellular, Lymphoid	1 [1.0]			
Inflammation, Chronic Active	1 [3.0]	1 [3.0]	2 [2.5]	1 [4.0]
Mineralization		2 [1.5]		1 [2.0]
Necrosis				3 [2.0]
Artery, Hyperplasia	1 [2.0]			
Artery, Inflammation, Chronic Active	2 [2.5]	2 [2.5]		
Myocardium, Necrosis		1 [3.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(49)	(50)
Accessory Adrenal Cortical Nodule		2 [1.5]	4 [1.8]	
Amyloid Deposition			1 [3.0]	
Hematopoietic Cell Proliferation			1 [1.0]	
Hyperplasia	1 [2.0]			
Hypertrophy	9 [1.7]	5 [1.0]	1 [2.0]	
Bilateral, Accessory Adrenal Cortical Nodule				1 [2.0]
Subcapsular, Hyperplasia	45 [1.3]	38 [1.2]	37 [1.3]	27 [1.0]
Islets, Pancreatic	(50)	(50)	(49)	(50)
Hyperplasia	5 [2.6]	3 [2.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Parathyroid Gland	(45)	(47)	(46)	(44)
Cyst	1 [2.0]			
Cyst, Multiple		1 [2.0]		
Pituitary Gland	(49)	(50)	(48)	(50)
Pars Distalis, Cyst	2 [1.5]	4 [2.0]	1 [2.0]	3 [1.3]
Pars Distalis, Cyst, Multiple	1 [2.0]			1 [2.0]
Thyroid Gland	(50)	(50)	(49)	(50)
Inflammation, Chronic Active	2 [2.5]			
Follicle, Cyst		1 [2.0]		
Follicle, Degeneration	1 [1.0]			
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Coagulating Gland	(50)	(50)	(49)	(50)
Atrophy	1 [4.0]			
Dilatation	9 [1.3]	16 [2.6]	36 [2.6]	47 [3.0]
Fibrosis		6 [2.0]	23 [2.5]	30 [3.0]
Infiltration Cellular, Lymphoid	3 [1.0]	6 [1.3]	2 [1.0]	
Inflammation, Chronic Active		6 [1.7]	22 [2.2]	33 [1.9]
Epithelium, Hyperplasia	1 [2.0]	1 [2.0]	5 [3.4]	1 [4.0]
Ductus Deferens	(50)	(50)	(49)	(50)
Inflammation, Chronic Active			3 [3.0]	
Epididymis	(50)	(50)	(49)	(50)
Atrophy	1 [4.0]			
Cyst		1 [3.0]	1 [2.0]	
Granuloma Sperm	1 [4.0]	3 [2.3]	6 [3.3]	8 [3.0]
Infiltration Cellular, Lymphoid	40 [1.2]	30 [1.2]	21 [1.0]	15 [1.0]
Inflammation, Chronic Active		3 [2.0]	2 [3.0]	
Preputial Gland	(50)	(50)	(49)	(50)
Atrophy	20 [3.4]	23 [3.3]	24 [3.3]	9 [2.9]
Infiltration Cellular, Lymphoid	18 [1.6]	3 [1.3]		
Inflammation, Chronic Active		7 [1.7]	3 [2.0]	2 [3.5]
Duct, Ectasia	19 [3.4]	15 [3.3]	23 [3.1]	10 [3.1]
Prostate	(50)	(50)	(49)	(50)
Fibrosis		1 [4.0]	3 [2.7]	1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Infiltration Cellular, Lymphoid	42 [1.3]	43 [1.7]	26 [1.7]	9 [1.4]
Inflammation, Chronic Active	3 [1.3]	10 [2.8]	27 [2.7]	44 [2.2]
Mineralization	1 [1.0]			
Artery, Hyperplasia	1 [3.0]			
Artery, Inflammation, Chronic Active	1 [2.0]			
Epithelium, Hyperplasia	4 [2.0]		1 [4.0]	
Seminal Vesicle	(50)	(50)	(49)	(50)
Atrophy	1 [4.0]			
Dilatation	12 [2.3]	14 [2.9]	38 [2.9]	41 [3.4]
Fibrosis		3 [2.0]	18 [2.7]	29 [2.9]
Inflammation, Chronic Active		4 [2.3]	14 [2.6]	22 [2.0]
Epithelium, Hyperplasia		1 [3.0]	5 [3.0]	1 [2.0]
Testes	(50)	(50)	(49)	(50)
Mineralization	1 [2.0]	1 [1.0]	3 [1.7]	2 [2.0]
Germinal Epithelium, Degeneration	8 [2.0]	1 [2.0]	3 [2.7]	3 [2.0]

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(49)	(50)
Hyperplasia	13 [4.0]	10 [4.0]	17 [3.9]	20 [4.0]
Myelofibrosis			1 [4.0]	
Erythroid Cell, Hyperplasia	1 [4.0]			
Lymph Node	(2)	(1)	(2)	(0)
Mediastinal, Hyperplasia, Lymphoid			1 [4.0]	
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Hematopoietic Cell Proliferation			1 [4.0]	
Hyperplasia, Lymphoid	3 [3.3]	7 [3.6]	7 [3.9]	
Hyperplasia, Plasma Cell		2 [3.0]	1 [2.0]	
Necrosis, Lymphoid			1 [3.0]	
Lymph Node, Mesenteric	(50)	(49)	(48)	(50)
Hyperplasia, Lymphoid	1 [4.0]		1 [3.0]	
Spleen	(50)	(50)	(49)	(49)
Amyloid Deposition		4 [2.0]	2 [1.5]	
Atrophy	2 [2.5]	9 [2.9]	30 [3.2]	39 [3.0]
Hematopoietic Cell Proliferation	18 [2.9]	16 [3.0]	12 [3.5]	7 [2.7]
Artery, Hyperplasia	1 [3.0]			
Artery, Inflammation, Chronic Active	1 [3.0]			
Lymphoid Follicle, Necrosis, Lymphoid			1 [2.0]	
Thymus	(41)	(42)	(40)	(49)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Atrophy	11 [3.5]	15 [3.9]	30 [3.9]	45 [3.7]
Cyst	5 [2.0]	2 [2.5]	5 [2.4]	5 [2.2]
Cyst, Multiple	19 [1.8]	28 [1.9]	27 [2.0]	35 [2.1]
Ectopic Parathyroid Gland	8 [1.9]	8 [1.8]	3 [1.7]	9 [2.0]
Inflammation, Chronic Active			1 [4.0]	
Thymocyte, Necrosis			2 [2.0]	3 [2.3]
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(49)	(50)
Cyst Epithelial Inclusion		1 [4.0]		
Hemorrhage			1 [1.0]	
Inflammation, Acute				1 [3.0]
Inflammation, Chronic Active	3 [2.7]	13 [3.3]	12 [3.3]	5 [3.4]
Dermis, Fibrosis	3 [3.0]	12 [3.0]	12 [3.1]	4 [3.5]
Dermis, Metaplasia, Osseous		1 [3.0]		
Epidermis, Hyperkeratosis		1 [4.0]		
Epidermis, Hyperplasia	3 [3.0]	13 [2.4]	12 [3.3]	6 [2.8]
Epidermis, Ulcer	3 [4.0]	13 [4.0]	11 [4.0]	6 [3.8]
Hair Follicle, Dilatation	7 [1.3]	10 [1.2]	13 [1.2]	28 [1.4]
Sebaceous Gland, Atrophy	13 [2.8]	10 [2.1]	20 [2.6]	29 [2.2]
Subcutaneous Tissue, Inflammation, Chronic Active				1 [2.0]
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(49)	(50)
Osteopetrosis		2 [3.0]	1 [4.0]	
Skeletal Muscle	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	2 [1.0]			
Inflammation, Chronic Active		1 [2.0]		
NERVOUS SYSTEM				
Brain	(50)	(50)	(49)	(50)
Degeneration		1 [1.0]		
Inflammation, Chronic Active	1 [2.0]			
Neuron, Necrosis			1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(49)	(50)
Congestion			1 [4.0]	
Fibrosis		1 [2.0]	1 [2.0]	
Infiltration Cellular, Lymphoid		4 [2.5]		
Inflammation, Chronic Active		2 [1.0]	1 [1.0]	1 [1.0]
Alveolar Epithelium, Hyperplasia	5 [2.2]	6 [2.2]	2 [2.5]	2 [2.5]
Alveolus, Infiltration Cellular, Histiocyte	4 [3.0]	6 [3.0]	1 [4.0]	
Mediastinum, Inflammation, Chronic Active		1 [3.0]		
Nose	(50)	(50)	(49)	(50)
Hemorrhage			1 [4.0]	
Inflammation, Chronic Active			1 [2.0]	
Nasolacrimal Duct, Inflammation, Chronic Active	1 [1.0]			
Nasolacrimal Duct, Squamous Epithelium, Hyperplasia	2 [1.5]			
Pleura	(1)	(1)	(1)	(0)
Trachea	(50)	(50)	(49)	(50)
Epithelium, Mineralization				1 [2.0]
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(49)	(50)
Atrophy			1 [2.0]	2 [4.0]
Anterior Chamber, Cornea, Inflammation, Suppurative	1 [4.0]			
Cornea, Inflammation, Chronic Active	1 [2.0]			
Cornea, Pigmentation			1 [1.0]	
Optic Nerve, Inflammation, Chronic Active		1 [3.0]		
Harderian Gland	(50)	(50)	(49)	(50)
Degeneration				1 [2.0]
Hyperplasia	3 [2.7]	2 [2.5]	1 [1.0]	
Infiltration Cellular, Lymphoid	33 [1.2]	26 [1.2]	7 [1.1]	1 [1.0]
Inflammation, Chronic Active		1 [2.0]		
Necrosis			1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
URINARY SYSTEM				
Kidney	(50)	(50)	(49)	(50)
Hydronephrosis	1 [2.0]	5 [2.6]	17 [2.4]	29 [2.3]
Infarct	4 [2.5]		1 [4.0]	
Infiltration Cellular, Lymphoid	39 [1.4]	38 [1.4]	12 [1.2]	3 [1.7]
Inflammation, Acute				3 [2.0]
Inflammation, Chronic Active			5 [3.2]	2 [2.5]
Metaplasia, Osseous	2 [1.5]	3 [1.7]	1 [2.0]	1 [2.0]
Mineralization	40 [1.0]	43 [1.0]	40 [1.2]	42 [1.3]
Nephropathy	47 [1.4]	45 [1.5]	28 [1.8]	24 [1.5]
Thrombosis				4 [2.5]
Artery, Inflammation, Chronic Active	2 [2.5]	1 [3.0]		
Cortex, Cyst	11 [2.0]	6 [1.7]	2 [2.0]	
Cortex, Cyst, Multiple			1 [4.0]	
Glomerulus, Amyloid Deposition		6 [2.3]	4 [1.8]	1 [1.0]
Papilla, Necrosis		3 [3.3]	3 [4.0]	
Pelvis, Hyperplasia	1 [1.0]			1 [2.0]
Renal Tubule, Dilatation	1 [2.0]	8 [2.6]	31 [3.0]	43 [2.9]
Renal Tubule, Hyperplasia	1 [2.0]			
Ureter	(43)	(45)	(47)	(50)
Dilatation		6 [3.0]	22 [3.0]	42 [2.8]
Inflammation, Chronic Active		3 [3.3]	24 [3.0]	39 [3.0]
Urethra	(48)	(50)	(49)	(50)
Dilatation		1 [4.0]	2 [4.0]	2 [4.0]
Inflammation, Chronic Active	1 [2.0]		1 [1.0]	
Artery, Hyperplasia	1 [4.0]			
Artery, Inflammation, Chronic Active	1 [3.0]			
Glands, Transitional Epithelium, Hyperplasia		17 [3.5]	2 [3.0]	
Transitional Epithelium, Inflammation, Chronic Active		1 [2.0]		
Urinary Bladder	(50)	(50)	(49)	(50)
Infiltration Cellular, Lymphoid	25 [1.1]	25 [1.0]	4 [1.0]	
Inflammation, Chronic Active		1 [2.0]	1 [1.0]	2 [2.0]
Transitional Epithelium, Hyperplasia		1 [2.0]		4 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 88148 - 07

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 02/27/2008

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
------------------	---------	---------	----------	----------

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident	1		1	1
Moribund Sacrifice	6	9	9	21
Natural Death	8	11	8	8
Survivors				
Natural Death				1
Terminal Sacrifice	35	30	32	19
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(49)	(50)	(50)	(50)
Perforation	1		1	1 [4.0]
Gallbladder	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid Inflammation, Chronic Active	3 [1.3]	3 [1.0]	2 [1.0] 1 [3.0]	1 [1.0]
Intestine Large, Cecum	(49)	(50)	(49)	(50)
Inflammation, Chronic Active Ulcer		1 [4.0] 1 [4.0]		
Intestine Large, Colon	(49)	(50)	(49)	(50)
Intestine Large, Rectum	(49)	(50)	(50)	(50)
Inflammation, Chronic Active	1 [3.0]			
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Intestine Small, Jejunum	(49)	(50)	(50)	(50)
Peyer's Patch, Hyperplasia, Lymphoid			1 [4.0]	3 [4.0]
Liver	(49)	(50)	(50)	(50)
Amyloid Deposition			2 [3.5]	4 [2.5]
Basophilic Focus	1	6	3	1
Clear Cell Focus	2	1	1	
Eosinophilic Focus	2		1	1
Hematopoietic Cell Proliferation	3 [1.3]	9 [1.3]	9 [1.6]	21 [1.7]
Infarct				3 [3.0]
Infiltration Cellular, Histiocyte				1 [3.0]
Infiltration Cellular, Lymphoid	38 [1.4]	40 [1.1]	38 [1.2]	28 [1.4]
Inflammation, Chronic Active	39 [1.2]	37 [1.3]	37 [1.2]	32 [1.2]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Mineralization		1 [1.0]		1 [1.0]
Mixed Cell Focus	3	3	4	1
Tension Lipidosis	4 [2.3]	6 [1.8]	4 [2.5]	4 [2.5]
Bile Duct, Hyperplasia		1 [2.0]		2 [2.0]
Bile Duct, Inflammation, Chronic Active				1 [2.0]
Hepatocyte, Necrosis	1 [2.0]	1 [1.0]	3 [2.3]	3 [1.7]
Hepatocyte, Vacuolization Cytoplasmic	33 [1.6]	33 [2.0]	35 [2.1]	20 [1.8]
Mesentery	(5)	(12)	(9)	(15)
Congestion			1 [3.0]	
Fat, Cyst	1 [4.0]			
Fat, Fibrosis	3 [1.7]	6 [2.5]	5 [2.6]	6 [2.5]
Fat, Inflammation, Chronic Active	2 [1.5]	6 [2.0]	4 [2.0]	7 [1.9]
Fat, Mineralization		1 [1.0]	3 [1.3]	
Fat, Necrosis	3 [4.0]	5 [4.0]	5 [4.0]	8 [4.0]
Pancreas	(49)	(50)	(50)	(50)
Basophilic Focus	1 [2.0]			
Congestion				1 [2.0]
Infiltration Cellular, Lymphoid	12 [1.2]	5 [1.0]	6 [1.3]	3 [2.0]
Inflammation, Chronic Active			2 [2.5]	1 [2.0]
Mineralization				1 [2.0]
Acinus, Atrophy		1 [3.0]		
Duct, Cyst		1 [4.0]		
Duct, Cyst, Multiple				1 [4.0]
Salivary Glands	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	36 [1.5]	23 [1.0]	13 [1.0]	1 [1.0]
Mineralization		1 [1.0]		
Stomach, Forestomach	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	2 [1.0]		2 [1.5]	10 [1.7]
Inflammation, Chronic Active	1 [2.0]	4 [2.3]	1 [3.0]	1 [1.0]
Mineralization				1 [1.0]
Epithelium, Cyst		1 [2.0]	2 [2.0]	
Epithelium, Hyperplasia	8 [1.9]	27 [1.5]	38 [1.7]	43 [2.0]
Epithelium, Ulcer	1 [1.0]	3 [3.0]	1 [4.0]	
Stomach, Glandular	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	1 [1.0]	14 [1.4]	30 [1.7]	28 [1.7]
Infiltration Cellular, Mast Cell	1 [2.0]			
Inflammation, Chronic Active	2 [2.0]		1 [2.0]	1 [2.0]
Mineralization	1 [1.0]	4 [1.0]	3 [1.0]	3 [1.7]
Epithelium, Erosion		1 [2.0]		
Epithelium, Hyperplasia, Focal	1 [2.0]	19 [1.5]	26 [1.9]	28 [2.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Epithelium, Necrosis			1 [3.0]	
Epithelium, Ulcer		1 [3.0]		1 [2.0]
Epithelium, Glands, Cyst	8 [1.6]	19 [1.3]	13 [1.2]	22 [1.8]
Tongue	(0)	(1)	(0)	(1)
Tooth	(2)	(0)	(0)	(0)
Malformation	2			
CARDIOVASCULAR SYSTEM				
Blood Vessel	(49)	(50)	(50)	(50)
Aorta, Mineralization	1 [1.0]	2 [3.0]		1 [2.0]
Heart	(49)	(50)	(50)	(50)
Cardiomyopathy	3 [1.3]	5 [1.2]	4 [1.3]	9 [1.7]
Hyperplasia, Atypical				1 [2.0]
Inflammation, Chronic Active		1 [2.0]		1 [2.0]
Mineralization	3 [1.7]	3 [1.3]	3 [1.7]	2 [2.0]
Valve, Inflammation, Chronic Active		1 [4.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	2 [2.5]	2 [1.5]	1 [2.0]	1 [2.0]
Cyst	1 [3.0]			
Degeneration, Fatty				1 [2.0]
Hematopoietic Cell Proliferation		2 [2.0]	1 [1.0]	
Hyperplasia	1 [2.0]			
Hypertrophy	2 [1.0]			
Inflammation, Chronic Active				1 [1.0]
Subcapsular, Hyperplasia	48 [2.1]	50 [2.0]	47 [2.0]	48 [2.0]
Adrenal Medulla	(49)	(50)	(50)	(50)
Hyperplasia	2 [1.0]		2 [2.0]	
Islets, Pancreatic	(49)	(50)	(50)	(50)
Hyperplasia	1 [2.0]			
Parathyroid Gland	(43)	(47)	(48)	(41)
Cyst		1 [2.0]		
Cyst, Multiple		1 [2.0]		1 [2.0]
Pituitary Gland	(49)	(49)	(50)	(50)
Pars Distalis, Angiectasis	2 [2.0]	1 [1.0]	3 [1.7]	2 [3.0]
Pars Distalis, Cyst				1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Pars Distalis, Hyperplasia Thyroid Gland	6 [2.0] (49)	5 [2.0] (50)	8 [2.3] (50)	5 [2.4] (50)
Ectopic Thymus	1 [2.0]		2 [1.5]	
Infiltration Cellular, Lymphoid C-cell, Hyperplasia	1 [1.0]		1 [4.0]	
Follicle, Cyst	1 [3.0]	1 [2.0]		1 [3.0]
Follicle, Degeneration	17 [1.8]	28 [2.1]	24 [2.1]	20 [2.0]

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

Clitoral Gland	(49)	(50)	(49)	(50)
Atrophy	25 [3.3]	44 [3.3]	37 [3.6]	40 [3.6]
Fibrosis				1 [2.0]
Infiltration Cellular, Lymphoid		5 [1.6]	6 [1.2]	3 [2.0]
Inflammation, Chronic Active	3 [1.7]	4 [1.5]	17 [2.1]	25 [2.3]
Duct, Cyst	5 [3.0]	46 [2.6]	43 [3.1]	43 [3.5]
Ovary	(49)	(50)	(50)	(50)
Angiectasis	3 [2.3]			
Atrophy	29 [3.3]	44 [3.4]	47 [3.4]	45 [3.7]
Cyst	11 [2.1]	8 [2.1]	5 [3.0]	4 [2.3]
Cyst, Multiple	1 [2.0]			
Infiltration Cellular, Lymphoid	2 [2.0]			
Inflammation, Chronic Active		1 [4.0]		
Mineralization	1 [1.0]			
Pigmentation	2 [1.5]			
Bilateral, Cyst		1 [2.0]		
Oviduct	(0)	(0)	(1)	(0)
Inflammation, Chronic Active			1 [3.0]	
Uterus	(49)	(50)	(50)	(50)
Cyst		1 [3.0]	1 [2.0]	
Infiltration Cellular, Lymphoid	1 [2.0]			
Inflammation, Chronic Active			1 [2.0]	
Endometrium, Hyperplasia, Cystic	45 [2.6]	45 [2.1]	45 [2.2]	41 [1.8]
Vagina	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	1 [1.0]			1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Epithelium, Atrophy Epithelium, Hyperplasia	11 [2.1] 2 [2.0] 3 [2.7]	21 [1.7] 2 [2.0] 1 [3.0]	15 [1.7] 3 [2.3] 3 [2.0]	18 [1.9] 3 [1.7]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hyperplasia	2 [4.0]	8 [4.0]	9 [4.0]	16 [4.0]
Myelofibrosis	16 [1.8]	30 [1.7]	33 [1.9]	15 [1.6]
Lymph Node	(7)	(8)	(9)	(16)
Bronchial, Hyperplasia, Lymphoid	1 [3.0]			
Inguinal, Hyperplasia, Lymphoid	1 [3.0]			
Inguinal, Pigmentation				1 [2.0]
Mediastinal, Hematopoietic Cell Proliferation		1 [1.0]		
Mediastinal, Hyperplasia, Lymphoid		1 [3.0]	2 [3.5]	1 [4.0]
Mediastinal, Inflammation, Chronic Active			1 [4.0]	
Mediastinal, Necrosis, Lymphoid	1 [3.0]			
Pancreatic, Hematopoietic Cell Proliferation				1 [1.0]
Pancreatic, Hyperplasia, Lymphoid				1 [4.0]
Pancreatic, Pigmentation				1 [2.0]
Renal, Hyperplasia, Lymphoid				1 [4.0]
Lymph Node, Mandibular	(49)	(49)	(50)	(49)
Hyperplasia, Lymphoid	10 [3.6]	8 [3.9]	9 [3.7]	15 [3.9]
Necrosis, Lymphoid	1 [3.0]			1 [4.0]
Pigmentation		1 [2.0]	1 [2.0]	2 [2.0]
Lymph Node, Mesenteric	(48)	(49)	(48)	(49)
Hyperplasia, Lymphoid	3 [3.0]		4 [3.8]	2 [3.5]
Mineralization		1 [2.0]		
Artery, Mineralization		1 [2.0]		
Spleen	(49)	(50)	(50)	(50)
Amyloid Deposition			1 [1.0]	4 [1.8]
Atrophy	1 [4.0]	3 [3.7]	6 [2.8]	3 [3.3]
Fibrosis		1 [1.0]		
Hematopoietic Cell Proliferation	10 [3.0]	25 [2.7]	21 [2.6]	33 [2.7]
Hyperplasia, Lymphoid			1 [3.0]	
Infarct				1 [4.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Lymphoid Follicle, Hyperplasia	8 [3.6]		1 [4.0]	1 [3.0]
Thymus	(48)	(48)	(45)	(48)
Atrophy	7 [3.3]	15 [3.5]	12 [3.9]	25 [3.8]
Cyst	9 [1.9]	5 [1.8]	4 [1.8]	3 [2.7]
Cyst, Multiple	21 [2.0]	31 [2.1]	33 [2.1]	37 [2.9]
Ectopic Parathyroid Gland	10 [1.9]	11 [1.6]	20 [1.9]	5 [2.0]
Ectopic Thyroid	1 [2.0]			
Hyperplasia, Lymphoid	2 [3.0]			
Infiltration Cellular, Histiocyte		1 [4.0]		
Inflammation, Chronic Active		5 [2.0]	12 [1.8]	5 [2.6]
Thymocyte, Necrosis	1 [3.0]	1 [4.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(49)	(50)	(50)	(50)
Skin	(49)	(50)	(50)	(50)
Inflammation, Chronic Active		2 [3.0]	6 [3.2]	11 [3.6]
Dermis, Fibrosis		1 [4.0]	4 [3.8]	11 [3.3]
Epidermis, Hyperplasia	1 [2.0]	2 [2.5]	4 [3.8]	11 [3.2]
Epidermis, Ulcer		1 [4.0]	4 [4.0]	11 [4.0]
Hair Follicle, Dilatation	2 [1.0]		11 [1.3]	23 [1.4]
Sebaceous Gland, Atrophy	6 [2.2]	10 [2.7]	11 [2.9]	15 [3.0]
Subcutaneous Tissue, Inflammation, Chronic Active			2 [2.5]	
Subcutaneous Tissue, Metaplasia, Osseous			1 [1.0]	
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Osteopetrosis				1 [3.0]
Skeletal Muscle	(4)	(5)	(1)	(8)
Infiltration Cellular, Lymphoid	1 [1.0]			
Inflammation, Chronic Active		1 [2.0]		
Mineralization				1 [1.0]
NERVOUS SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Brain	(49)	(50)	(50)	(50)
Compression	1 [4.0]	1 [3.0]		
Hydrocephalus	1 [3.0]			
Infiltration Cellular, Lymphoid	1 [1.0]			
Meninges, Hemorrhage		1 [2.0]		
Neuron, Necrosis	2 [1.5]			
Peripheral Nerve	(0)	(2)	(1)	(0)
Sciatic, Degeneration		1 [2.0]		
Spinal Cord	(0)	(1)	(1)	(0)
Degeneration		1 [3.0]	1 [2.0]	
RESPIRATORY SYSTEM				
Lung	(49)	(50)	(50)	(50)
Hemorrhage				1 [3.0]
Infiltration Cellular, Lymphoid	4 [2.3]	2 [2.0]		2 [3.5]
Infiltration Cellular, Polymorphonuclear		1 [4.0]		
Inflammation, Chronic Active		3 [1.3]	5 [1.6]	7 [2.6]
Alveolar Epithelium, Hyperplasia	1 [1.0]	1 [1.0]	1 [2.0]	4 [2.8]
Alveolar Epithelium, Metaplasia, Squamous				1 [2.0]
Alveolus, Infiltration Cellular, Histiocyte		3 [2.7]	1 [1.0]	6 [3.5]
Artery, Mineralization		1 [1.0]		
Artery, Mediastinum, Mineralization	1 [2.0]	1 [2.0]		
Bronchiole, Metaplasia, Squamous				1 [2.0]
Mediastinum, Inflammation	1 [3.0]			
Nose	(50)	(50)	(50)	(50)
Inflammation, Chronic Active	4 [2.3]			
Glands, Olfactory Epithelium, Dilatation				2 [2.5]
Glands, Olfactory Epithelium, Hyperplasia	1 [3.0]			
Olfactory Epithelium, Metaplasia	1 [2.0]			
SPECIAL SENSES SYSTEM				
Ear	(1)	(0)	(1)	(2)
Inflammation, Chronic Active	1 [1.0]			
Eye	(49)	(50)	(50)	(49)
Atrophy	1 [4.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Cornea, Inflammation, Chronic Active				1 [2.0]
Optic Nerve, Infiltration Cellular, Lymphoid			1 [2.0]	1 [2.0]
Optic Nerve, Pigmentation				1 [2.0]
Harderian Gland	(49)	(50)	(49)	(49)
Atrophy	1 [3.0]			
Hyperplasia	2 [2.5]	3 [3.0]	2 [2.5]	2 [3.0]
Infiltration Cellular, Lymphoid	32 [1.3]	13 [1.1]	7 [1.0]	4 [1.0]
Inflammation, Chronic Active	1 [1.0]		2 [1.0]	3 [1.7]
URINARY SYSTEM				
Kidney	(49)	(50)	(50)	(50)
Hydronephrosis			5 [3.2]	3 [3.7]
Infarct	3 [4.0]	6 [2.5]	11 [3.6]	2 [4.0]
Infiltration Cellular, Lymphoid	39 [1.5]	35 [1.5]	37 [1.2]	26 [1.2]
Inflammation, Chronic Active				2 [3.5]
Metaplasia, Osseous		2 [2.0]		
Mineralization	6 [1.0]	14 [1.2]	13 [1.2]	14 [1.6]
Nephropathy	29 [1.1]	32 [1.3]	38 [1.7]	41 [1.5]
Cortex, Cyst	1 [2.0]			
Cortex, Cyst, Multiple	1 [2.0]			
Glomerulus, Amyloid Deposition			1 [2.0]	5 [2.6]
Papilla, Necrosis		1 [4.0]	8 [3.8]	2 [4.0]
Pelvis, Metaplasia, Osseous				1 [2.0]
Renal Tubule, Accumulation, Hyaline Droplet	1 [4.0]	2 [3.0]	2 [3.0]	2 [3.0]
Renal Tubule, Dilatation	1 [3.0]	5 [2.4]	6 [2.7]	7 [3.0]
Renal Tubule, Pigmentation	1 [2.0]			
Ureter	(0)	(1)	(0)	(2)
Transitional Epithelium, Hyperplasia				1 [2.0]
Urethra	(49)	(50)	(49)	(49)
Dilatation			1 [4.0]	
Infiltration Cellular, Lymphoid				1 [2.0]
Inflammation, Suppurative			1 [4.0]	
Glands, Transitional Epithelium, Hyperplasia		4 [2.0]		3 [2.7]
Urinary Bladder	(49)	(50)	(50)	(50)
Infiltration Cellular, Lymphoid	41 [1.4]	30 [1.1]	27 [1.1]	25 [1.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Inflammation, Chronic Active				2 [2.5]
Transitional Epithelium, Hyperplasia				4 [2.5]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)